V
Voyager Therapeutics Inc (VYGR)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
$1.63
-0.10 (-5.78%)
Market Cap: $107.66M
Last updated: Nov 17, 2026 at 11:03 AM ET
Voyager Therapeutics Inc (VYGR) Valuation Multiples
Voyager Therapeutics (VYGR) trades at 4.0x sales and 0.7x book value. Its P/S of 4.0x is above its 5-year median of 3.8x. Its forward P/E is 8.4x.
Current Multiples
| Multiple | Value |
|---|---|
| P/E (trailing) | N/A |
| Forward P/E | 8.4x |
| Price to sales | 4.0x |
| Price to book | 0.7x |
| PEG | N/A |
Historical Medians
Against its 10-year medians, its P/S is 29.8% below 5.7x and its P/B is 66.7% below 2.1x.
| Multiple | Current | 5-year median | 10-year median |
|---|---|---|---|
| P/S | 4.0x | 3.8x | 5.7x |
| P/B | 0.7x | 1.4x | 2.1x |
Valuation History
Over the 10 year ends shown, its P/S ranged from 1.4x in 2023 to 45.8x in 2017.
| Year end | Price | P/E | P/S | P/B |
|---|---|---|---|---|
| 2025 | $3.93 | N/A | 5.7x | 1.2x |
| 2024 | $5.67 | N/A | 4.1x | 1.1x |
| 2023 | $8.44 | 2.7x | 1.4x | 1.6x |
| 2022 | $6.10 | N/A | 5.7x | 4.0x |
| 2021 | $2.71 | N/A | 2.7x | 1.1x |
| 2020 | $7.15 | 7.5x | 1.6x | 1.7x |
| 2019 | $13.95 | N/A | 4.9x | 5.2x |
| 2018 | $9.40 | N/A | 39.6x | 6.5x |
| 2017 | $16.60 | N/A | 45.8x | 3.6x |
| 2016 | $12.74 | N/A | 22.6x | 2.4x |
GNG Valuation
| GNG view | Undervalued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About VYGR
What is VYGR's forward P/E ratio?
Voyager Therapeutics has a forward P/E ratio of 8.4x.
Is VYGR stock overvalued?
GNG's valuation label for VYGR is Undervalued.
What is VYGR's price to sales ratio?
Voyager Therapeutics has a price to sales ratio of 4.0x.
VYGR pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors